Herceptin Research Today is a free monthly online journal that collates and summarizes the latest research about Herceptin, including details on side-effects, breast cancer, treatment, therapy.

Volume 5 (2008), Issue 4 (April)

1. Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab.
   Cancer Chemother Pharmacol. [Abstract] [Full-text]
2. Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenografts.
   Clin Cancer Res, 14(7): 2171-9. [Abstract] [Full-text]
3. V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs--rituximab and trastuzumab.
   Int J Cancer, 122(11): 2526-34. [Abstract] [Full-text]
4. PAMAM dendrimer-based contrast agents for MR imaging of Her-2/neu receptors by a three-step pretargeting approach.
   Magn Reson Med, 59(4): 679-85. [Abstract] [Full-text]
5. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
   J Clin Oncol, 26(11): 1810-6. [Abstract] [Full-text]
6. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.
   J Clin Oncol, 26(11): 1789-96. [Abstract] [Full-text]
7. EGFR and ErbB2 are functionally coupled to CD44 and regulate shedding, internalization and motogenic effect of CD44.
   Cancer Lett, 263(2): 231-42. [Abstract] [Full-text]
8. Lapatinib: A Sword With Two Edges.
   Pathol Oncol Res. [Abstract] [Full-text]
9. Nanoelectrode ensembles as recognition platform for electrochemical immunosensors.
   Biosens Bioelectron. [Abstract] [Full-text]
10. Biological therapy of salivary duct carcinoma.
    J Laryngol Otol. [Abstract] [Full-text]
11. A novel bifunctional maleimido CHX-A'' chelator for conjugation to thiol-containing biomolecules.
    Bioorg Med Chem Lett, 18(8): 2679-83. [Abstract] [Full-text]
12. Issues and controversies in the treatment of HER2 positive metastatic breast cancer.
    Breast Cancer Res Treat, 109(1): 1-7. [Abstract] [Full-text]
13. Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer.
    Cancer Chemother Pharmacol, 62(1): 159-64. [Abstract] [Full-text]
14. Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy.
    Head Neck, 30(5): 680-3. [Abstract] [Full-text]
15. Contact spotting of protein microarrays coupled with spike-in of normalizer protein permits time-resolved analysis of ERBB receptor signaling.
    Proteomics, 8(8): 1586-94. [Abstract] [Full-text]
16. Phenotypic and Genetic Characterization of Circulating Tumor Cells by Combining Immunomagnetic Selection and FICTION Techniques.
    J Histochem Cytochem. [Abstract] [Full-text]
17. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.
    J Clin Oncol, 26(12): 1993-9. [Abstract] [Full-text]
18. Jab1 is overexpressed in human breast cancer and is a downstream target for HER-2/neu.
    Mod Pathol, 21(5): 609-16. [Abstract] [Full-text]
19. Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines.
    Lab Invest, 88(5): 491-503. [Abstract] [Full-text]
20. Prognostic significance of HER-2 status in women with inflammatory breast cancer.
    Cancer, 112(9): 1905-11. [Abstract] [Full-text]
21. Radioembolization in patients with hepatic metastases from breast cancer.
    J Vasc Interv Radiol, 19(5): 683-90. [Abstract] [Full-text]

© 2004-2008 Herceptin Research Today. All Rights Reserved.